Company: Oxigene ( OXGN) Drug/indication: Zybrestat for non-small cell lung cancer Clinical trial event: Phase II results Timing: 2009 The phase II study adds Zybrestat to a standard first-line regimen for lung cancer for Avastin and chemotherapy. The study enrolled 60 patients and is using progression-free survival as the primary endpoint. Company: Protalix Biotherapeutics ( PLX) Drug/indication: prGCD for Gaucher's disease Clinical trial event: Phase III results Timing: Fourth quarter Protalix says it will seek FDA approval for prGCD if results are positive from this pivotal phase III study. The drug, if approved, would compete against Genzyme's Cerezyme. Company: Repros Therapeutics ( RPRX) Drug/indication: Proellex for uterine fibroids Clinical trial event: Phase III results Timing: Fourth quarter This is the first of two phase III studies required for Repros to seek regulatory approval of Proellex. Results from the second study are expected early next year. Company: Vertex Pharmaceuticals ( VRTX) Drug/indication: Telaprevir for hepatitis C Clinical trial event: Phase II twice-daily dosing data Timing: 2009 Vertex will release final data from a phase II study investigating whether telaprevir can be dosed twice daily instead of three times daily.